361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomes

361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomes

Bibliographic Details
Main Authors: Magnus Jaderberg, Victor Levitsky, Luis Paz-Ares, Lukasz Kuryk, Nicolas Isambert, Susana Cedres, Xavier Serres, Charles Ricordel, Santiago Ponce Aix, Anne-Sophie Moller, Sylvia Vetrhus
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:Journal for ImmunoTherapy of Cancer
id doaj-f73b789c28e84aa895fb38bc8393d2d1
record_format Article
spelling doaj-f73b789c28e84aa895fb38bc8393d2d12020-12-11T10:01:38ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.0361361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomesMagnus Jaderberg0Victor Levitsky1Luis Paz-Ares2Lukasz Kuryk3Nicolas Isambert4Susana Cedres5Xavier Serres6Charles Ricordel7Santiago Ponce Aix8Anne-Sophie Moller9Sylvia Vetrhus101Research and Development, Oslo, Norway1Research and Development, Oslo, Norway2Medical Oncology, Sevilla, Spain1Research and Development, Oslo, Norway2Medical Oncology, Sevilla, Spain2Medical Oncology, Sevilla, Spain3Radiology, Barcelona, Spain4Pulmonology, Rennes, France2Medical Oncology, Sevilla, Spain1Research and Development, Oslo, Norway1Research and Development, Oslo, Norway
collection DOAJ
language English
format Article
sources DOAJ
author Magnus Jaderberg
Victor Levitsky
Luis Paz-Ares
Lukasz Kuryk
Nicolas Isambert
Susana Cedres
Xavier Serres
Charles Ricordel
Santiago Ponce Aix
Anne-Sophie Moller
Sylvia Vetrhus
spellingShingle Magnus Jaderberg
Victor Levitsky
Luis Paz-Ares
Lukasz Kuryk
Nicolas Isambert
Susana Cedres
Xavier Serres
Charles Ricordel
Santiago Ponce Aix
Anne-Sophie Moller
Sylvia Vetrhus
361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomes
Journal for ImmunoTherapy of Cancer
author_facet Magnus Jaderberg
Victor Levitsky
Luis Paz-Ares
Lukasz Kuryk
Nicolas Isambert
Susana Cedres
Xavier Serres
Charles Ricordel
Santiago Ponce Aix
Anne-Sophie Moller
Sylvia Vetrhus
author_sort Magnus Jaderberg
title 361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomes
title_short 361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomes
title_full 361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomes
title_fullStr 361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomes
title_full_unstemmed 361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomes
title_sort 361 a randomised open-label phase i/ii study adding oncos-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomes
publisher BMJ Publishing Group
series Journal for ImmunoTherapy of Cancer
issn 2051-1426
publishDate 2020-11-01
work_keys_str_mv AT magnusjaderberg 361arandomisedopenlabelphaseiiistudyaddingoncos102topemetrexedcisplatininpatientswithunresectablemalignantpleuralmesothelioma12monthanalysisofbiomarkersandclinicaloutcomes
AT victorlevitsky 361arandomisedopenlabelphaseiiistudyaddingoncos102topemetrexedcisplatininpatientswithunresectablemalignantpleuralmesothelioma12monthanalysisofbiomarkersandclinicaloutcomes
AT luispazares 361arandomisedopenlabelphaseiiistudyaddingoncos102topemetrexedcisplatininpatientswithunresectablemalignantpleuralmesothelioma12monthanalysisofbiomarkersandclinicaloutcomes
AT lukaszkuryk 361arandomisedopenlabelphaseiiistudyaddingoncos102topemetrexedcisplatininpatientswithunresectablemalignantpleuralmesothelioma12monthanalysisofbiomarkersandclinicaloutcomes
AT nicolasisambert 361arandomisedopenlabelphaseiiistudyaddingoncos102topemetrexedcisplatininpatientswithunresectablemalignantpleuralmesothelioma12monthanalysisofbiomarkersandclinicaloutcomes
AT susanacedres 361arandomisedopenlabelphaseiiistudyaddingoncos102topemetrexedcisplatininpatientswithunresectablemalignantpleuralmesothelioma12monthanalysisofbiomarkersandclinicaloutcomes
AT xavierserres 361arandomisedopenlabelphaseiiistudyaddingoncos102topemetrexedcisplatininpatientswithunresectablemalignantpleuralmesothelioma12monthanalysisofbiomarkersandclinicaloutcomes
AT charlesricordel 361arandomisedopenlabelphaseiiistudyaddingoncos102topemetrexedcisplatininpatientswithunresectablemalignantpleuralmesothelioma12monthanalysisofbiomarkersandclinicaloutcomes
AT santiagoponceaix 361arandomisedopenlabelphaseiiistudyaddingoncos102topemetrexedcisplatininpatientswithunresectablemalignantpleuralmesothelioma12monthanalysisofbiomarkersandclinicaloutcomes
AT annesophiemoller 361arandomisedopenlabelphaseiiistudyaddingoncos102topemetrexedcisplatininpatientswithunresectablemalignantpleuralmesothelioma12monthanalysisofbiomarkersandclinicaloutcomes
AT sylviavetrhus 361arandomisedopenlabelphaseiiistudyaddingoncos102topemetrexedcisplatininpatientswithunresectablemalignantpleuralmesothelioma12monthanalysisofbiomarkersandclinicaloutcomes
_version_ 1724386628771774464

Similar Items